Gilead Sciences, Inc. (NASDAQ:GILD) declined 2.93% to end last trading session at $101.38. The company, on November 23, 2015, declared that the European Commission has granted marketing authorization for the once-daily single tablet regimen Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive marketing authorization in the European Union (EU).
Genvoya is indicated in the EU for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with HIV-1 without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 2.45% to finish last trading session at $36.28. The company, on November 17, 2015, declared that the Annals of Neurology published online [link to final article] positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients experienced a slower rate of disease progression when compared to untreated matched historical controls and the investigational drug continued to be well-tolerated.
This analysis used historical data from the Italian Telethon Network and the Leuven Neuromuscular Reference Group for comparative analysis of 6MWT performance at baseline and Months 12, 24, and 36. Patients were matched to the eteplirsen group based on age, corticosteroid use and genotype.
Geron Corporation (NASDAQ:GERN) decreased 2.38% to complete last trading session at $4.93. The company, on Nov. 30, 2015, declared that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conference:
- Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015.
Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting:
- The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015.
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.